HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...

A new study published in the Annals of Medicine and Surgery showed that the severity of acne was not significantly correlated ...

“The influencers do not lie,” says one reviewer. “This stuff is magic!” ...

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...

As of Tuesday, January 13, Sensus Healthcare, Inc.’s SRTS share price has surged by 10.65%, which has investors questioning if this is right time to sell.

New Zealand's Kanuka oil is emerging as a potent skincare contender, challenging Manuka oil's reign.

From contrast therapy to rhythmic health, experts are placing renewed focus on recovery, rest, and repair. Read on for some ...